The safety and tolerability of single and multiple administration of DWP212525
Healthy adult volunteers aged 19 to 55 years
Those with a body weight ≥ 50.0 kg to ≤ 90.0 kg with a body mass index (BMI) of ≥ 18.0 kg/m2 to ≤ 30.0 kg/m2
Received a sufficient explanation on this study
Eligible as subjects in the study
History of diseases such as clinically significant disease of hepatobiliary
Following conditions applicable to clinically significant acute or chronic infections or the past history confirmed via an interview
Hemato-oncologic diseases, including malignant tumor diagnosis
Past history of tuberculosis infection or confirmed tuberculosis in the IGRA test and chest X-ray test
11
Treatment groupsSee each treatment group below.